Show simple item record

resumen

Abstract
Inactivated Foot-and-Mouth Disease (FMD) vaccine has proven to be effective in the control of the disease. However, its production has some disadvantages, including the costly biosafety facilities required for the production of huge amounts of growing live virus, the need of an exhaustive purification process to eliminate non-structural proteins of the virus in the final formulations in order to differentiate infected from vaccinated animals and variable [ver mas...]
dc.contributor.authorMignaqui, Ana Clara
dc.contributor.authorFerella, Alejandra
dc.contributor.authorCass, Brian
dc.contributor.authorMukankurayija, Larissa
dc.contributor.authorL’Abbé, Denis
dc.contributor.authorBisson, Louis
dc.contributor.authorSánchez, Cintia
dc.contributor.authorScian, Romina
dc.contributor.authorCardillo, Sabrina Beatriz
dc.contributor.authorDurocher, Yves
dc.contributor.authorWigdorovitz, Andres
dc.date.accessioned2020-12-28T16:45:30Z
dc.date.available2020-12-28T16:45:30Z
dc.date.issued2020-09
dc.identifier.issn2297-1769
dc.identifier.otherhttps://doi.org/10.3389/fvets.2020.00601
dc.identifier.urihttp://hdl.handle.net/20.500.12123/8502
dc.identifier.urihttps://www.frontiersin.org/articles/10.3389/fvets.2020.00601/full
dc.description.abstractInactivated Foot-and-Mouth Disease (FMD) vaccine has proven to be effective in the control of the disease. However, its production has some disadvantages, including the costly biosafety facilities required for the production of huge amounts of growing live virus, the need of an exhaustive purification process to eliminate non-structural proteins of the virus in the final formulations in order to differentiate infected from vaccinated animals and variable local regulatory restrictions to produce and commercialize the vaccine. Thus, a novel vaccine against FMD that overcome these restrictions is desirable. Although many developments have been made in this regard, most of them failed in terms of efficacy or when considering their transferability to the industry. We have previously reported the use of transient gene expression in mammalian cells to produce FMD virus-like particles (VLPs) as a novel vaccine for FMD and demonstrated the immunogenicity of the recombinant structures in animal models. Here, we report the optimization of the production system by assaying different DNA:polyethylenimine concentrations, cell densities, and direct and indirect protocols of transfection. Also, we evaluated the reproducibility and scalability of the technology to produce high yields of recombinant VLPs in a cost-effective and scalable system compatible with industrial tech-transfer of an effective and safe vaccine.eng
dc.formatapplication/pdfes_AR
dc.language.isoenges_AR
dc.publisherFrontiers Media S.A.es_AR
dc.rightsinfo:eu-repo/semantics/openAccesses_AR
dc.sourceFrontiers in Veterinary Science 7 : art. 601 (2020)es_AR
dc.subjectVacuna Inactivadaes_AR
dc.subjectInactivated Vaccineseng
dc.subjectFiebre Aftosaes_AR
dc.subjectFoot and Mouth Diseaseeng
dc.subjectEnfermedades de los Animaleses_AR
dc.subjectAnimal Diseaseseng
dc.titleFoot-and-Mouth Disease: Optimization, Reproducibility, and Scalability of High-Yield Production of Virus-Like Particles for a Next-Generation Vaccinees_AR
dc.typeinfo:ar-repo/semantics/artículoes_AR
dc.typeinfo:eu-repo/semantics/articlees_AR
dc.typeinfo:eu-repo/semantics/publishedVersiones_AR
dc.description.origenEstación Experimental Agropecuaria Barilochees_AR
dc.description.filFil: Mignaqui, Ana Clara. Instituto Nacional de Tecnología Agropecuaria (INTA). Estación Experimental Agropecuaria Bariloche. Consejo Nacional de Investigaciones Cientificas y Tecnicas. Instituto de Investigaciones Forestales y Agropecuarias Bariloche; Argentinaes_AR
dc.description.filFil: Ferella, Alejandra. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología e Innovaciones Tecnológicas; Argentinaes_AR
dc.description.filFil: Cass, Brian. Human Health Therapeutics Research Center, National Research Council Canada; Canadáes_AR
dc.description.filFil Mukankurayija, Larissa. Human Health Therapeutics Research Center, National Research Council Canada; Canadáes_AR
dc.description.filFil: L’Abbé, Denis. Human Health Therapeutics Research Center, National Research Council Canada; Canadáes_AR
dc.description.filFil: Bisson, Louis. Human Health Therapeutics Research Center, National Research Council Canada; Canadaes_AR
dc.description.filFil: Sánchez, Cintia. Biogénesis-Bagó; Argentinaes_AR
dc.description.filFil: Scian, Romina. Biogénesis-Bagó; Argentinaes_AR
dc.description.filFil: Cardillo, Sabrina Beatriz. Biogénesis-Bagó; Argentinaes_AR
dc.description.filFil: Durocher, Yves. Human Health Therapeutics Research Center, National Research Council Canada; Canadáes_AR
dc.description.filFil: Wigdorovitz, Andres. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología e Innovaciones Tecnológicas; Argentinaes_AR
dc.subtypecientifico
dc.subtypecientifico


Files in this item

Thumbnail

This item appears in the following Collection(s)

common

Show simple item record